What is CellMosaic?
CellMosaic specializes in bioconjugation, offering a comprehensive suite of products and services that include Antibody Drug Conjugate (ADC) Kits, custom bioconjugation, and bioconjugate drug development. Leveraging advanced technologies like AqueaTether (AqT), the company facilitates the creation of next-generation bioconjugates and targeted therapeutics. CellMosaic primarily serves the pharmaceutical and biotechnology sectors, providing high-quality bioconjugation solutions to clients focused on developing novel treatments. Established in 2008, the company has built a reputation for innovation and excellence in this specialized field.
How much funding has CellMosaic raised?
CellMosaic has raised a total of $22K across 1 funding round:
Debt
$22K
Debt (2021): $22K with participation from PPP
Key Investors in CellMosaic
PPP
Public-Private Partnership
What's next for CellMosaic?
With the recent influx of substantial expansion capital, CellMosaic is strategically positioned to scale its operations and further its research and development initiatives. This funding is expected to bolster the company's capacity to deliver cutting-edge bioconjugation services and products, particularly in the development of Antibody Drug Conjugates. The company's focus on advanced technologies like AqueaTether suggests a trajectory towards pioneering new frontiers in targeted therapeutics, potentially leading to significant advancements in cancer treatment and other areas requiring precise drug delivery. Continued investment in this space indicates strong market confidence in CellMosaic's technological capabilities and its potential to capture a larger share of the biopharmaceutical market.
See full CellMosaic company page
